Françoise Mornex is Professor of Oncology at the University Claude Bernard, Lyon, France, and Chair of the Radiation Oncology Department in Lyon, Centre Hospitalier Lyon Sud, where she practises radiation and medical oncology.
Professor Mornex specializes in the field of combined chemoradiation, where she has taken a leadership role in the development of multi-modality treatment for lung tumors, and tumors of the digestive tract. Her current areas of research include development of novel chemoradiation regimens and the design of phases I, II and III randomized trials. She also has a major interest in the development of innovative radiation therapy techniques.
Professor Mornex is the General Secretary of the French Radiation Oncology Society (SFRO) since 2001; she belongs to the Conseil National des Universités, which designates the new French professors in the field of oncology and had functions of Counsellor for Radiation Oncology at the French National Institute of Cancer, Expert for the French Ministry of Health and the Autorité de Sûreté Nucléaire.
She joined the International Association for the Study of Lung Cancer (IASLC) in 1987, participated at the foundation of the Intergroupe Francophone de Cancérologie Thoracique (IFCT) as treasurer then as Board member, she is member of the American Society for Therapeutic Radiology and Oncology (ASTRO), the European Society for Therapeutic Radiology and Oncology (ESTRO), and the SFRO since her foundation in 1990.
Professor Mornex has published 230 articles, 2 books (lung cancer) and 15 book chapters in the fields of lung cancer, radiation oncology, combined chemoradiation, radiobiology, and radiation management and quality assurance. She is Associate Editor of the journal Cancer/ Radiothérapie (IF 1.5), and has been Associate Editor of the Journal of Thoracic Oncology, she is currently member of the International Advisory Board of the International Journal of Radiation Oncology, Biology and Physics. She has organized many national and international meetings in her fields of interest, including IASLC lung cancer workshop. She was the Co-President of the extremely successful First and the Second European IASLC-ESMO Lung cancer Conferences in Geneva, 2008 and 2010, in association with Raphael Rosell.
She will serve on the Board of Directors for four years, starting at the WCLC in 2013.
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.
Journal of Thoracic Oncology
The IASLC’s premier journal, emphasizing a multidisciplinary approach including original research (clinical trials and translational or basic research), reviews and opinion pieces. Visit JTO